Grünenthal Advances NaV 1.8 Inhibitor to Clinical Trials for Non-Opioid Relief
Grünenthal Group has initiated clinical development for its proprietary NaV 1.8 inhibitor, a major step toward providing a non-opioid alternative for pain management. This move positions the German pain specialist as a key competitor in the high-growth peripheral sodium channel inhibitor market.